"Baby Amelia Defies Odds Against Shared Genetic Condition"
Sisters Maisie and Amelia, born with spinal muscular atrophy (SMA), have had different outcomes due to the timing of their treatments. Maisie, diagnosed at two months, has improved with drugs like Spinraza and Zolgensma but may never walk unaided. Amelia, treated from birth, is expected to live a normal life. The UK has approved a new SMA drug, Evrysdi, for newborns, and campaigners are urging for routine NHS screening to ensure early treatment, which can be life-changing. Despite the availability of effective treatments, the lack of a screening program means many children may not receive timely care.